Literature DB >> 25584619

SARCOSPA - Sarcopenia in spondyloarthritis patients.

R Aguiar, J Sequeira, T Meirinhos, C Ambrósio, A Barcelos.   

Abstract

INTRODUCTION: The loss of muscle mass (MM) is a serious problem which has been demonstrated in patients with rheumatoid arthritis. There are few studies about the loss of MM in patients with spondyloarthritis (Spa).
OBJECTIVE: To assess muscle mass index (MMI) in a cohort of patients with Spa and compare it with a control group of healthy individuals; to verify if a higher risk of sarcopenia is related with disease activity, functional impairment, duration of the illness and radiological damage.
METHODS: Case control study. Muscle mass index (MMI) was determined, from the value of MM, using Lee's equation, in a cohort of patients with spondyloarthritis and in a control group. Bath Ankylosing Spondylitis Disease Activity and Function Indexes (BASDAI and BASFI), Ankylosing Spondylitis Quality of Life (ASQoL) and Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) were assessed in a cohort of patients with axial Spa, as well as Health Assessment Questionnaire (HAQ) and Disease Activity Score 28 (DAS28) in patients with peripheral disease. Data were treated using SPSS version 17.0. Values of p<0,05 were considered with statistical significance.
RESULTS: 60 patients were enrolled; 48.2% were males, mean age 45.5±13.4 years, mean disease duration 10.9±11.6 years; 36 had ankylosing spondylitis and 24 had psoriatic arthritis. 62% of patients had sarcopenia and there was a significant difference in mean MMI between patients and controls (7.65±0.98 vs 8.25±0.92; p=0.001, OR =5.23. In male patients, there was a statistically significant moderate negative correlation between MMI and BASDAI and BASFI (p=-0.536 and p=-0.445). No other significant correlations were identified.
CONCLUSION: Our study supports the hypothesis of a greater prevalence of sarcopenia in patients with Spa compared to healthy controls. Some limitations included the sample size, potential confounding factor such the bias of measurement and the use of a non-validated equation to Portuguese population to calculate MM.

Entities:  

Mesh:

Year:  2014        PMID: 25584619

Source DB:  PubMed          Journal:  Acta Reumatol Port        ISSN: 0303-464X            Impact factor:   1.290


  7 in total

Review 1.  Ultrasound and magnetic resonance imaging as diagnostic tools for sarcopenia in immune-mediated rheumatic diseases (IMRDs).

Authors:  Fausto Salaffi; Marina Carotti; Andrea Di Matteo; Luca Ceccarelli; Sonia Farah; Catalina Villota-Eraso; Marco Di Carlo; Andrea Giovagnoni
Journal:  Radiol Med       Date:  2022-09-20       Impact factor: 6.313

2.  Presarcopenia in Patients with Vitiligo: A Case Control Study.

Authors:  Faiq I Gorial; Sarah Khalaf Jehad; Salwa Faris Taha; Aseen Adil Tawfeeq
Journal:  Mediterr J Rheumatol       Date:  2021-05-28

Review 3.  Sarcopenia: A Rheumatic Disease?

Authors:  Sarthak Gupta; Robinder J S Dhillon; Sarfaraz Hasni
Journal:  Rheum Dis Clin North Am       Date:  2018-06-12       Impact factor: 2.670

4.  Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors.

Authors:  Michele Barone; Maria Teresa Viggiani; Maria Grazia Anelli; Rosalinda Fanizzi; Orsola Lorusso; Giuseppe Lopalco; Luca Cantarini; Alfredo Di Leo; Giovanni Lapadula; Florenzo Iannone
Journal:  J Clin Med       Date:  2018-12-01       Impact factor: 4.241

5.  Changes in body composition and bone mineral density in postmenopausal women with psoriatic arthritis.

Authors:  Magdalena Krajewska-Włodarczyk; Agnieszka Owczarczyk-Saczonek; Waldemar Placek
Journal:  Reumatologia       Date:  2017-10-28

Review 6.  Sarcopenia in Autoimmune and Rheumatic Diseases: A Comprehensive Review.

Authors:  Hyo Jin An; Kalthoum Tizaoui; Salvatore Terrazzino; Sarah Cargnin; Keum Hwa Lee; Seoung Wan Nam; Jae Seok Kim; Jae Won Yang; Jun Young Lee; Lee Smith; Ai Koyanagi; Louis Jacob; Han Li; Jae Il Shin; Andreas Kronbichler
Journal:  Int J Mol Sci       Date:  2020-08-07       Impact factor: 5.923

Review 7.  Can Biological Drugs Diminish the Risk of Sarcopenia in Psoriatic Patients? A Systematic Review.

Authors:  Zuzanna Piętowska; Danuta Nowicka; Jacek Szepietowski
Journal:  Life (Basel)       Date:  2022-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.